Champions Oncology Q4 Revenue Jumps 12% to $13.8M, Margins Improve on Cost Cuts
CSBR sits 27% above its 52-week low of $5.5.
Summary
Champions Oncology reported fiscal Q4 revenue of $13.8 million, up 12% year-over-year, with positive adjusted EBITDA and adjusted EPS of $0.01. The improvement was driven by cost discipline, including lower outsourced research expenses and bringing radiopharmaceutical activities in-house. This follows a Q3 net loss and significant cash burn, making the margin turnaround notable. The company did not provide specific guidance, but the shift to in-house capabilities could sustain margin gains. With the stock trading at 59x forward earnings, the market is pricing in continued improvement.
At the time of this announcement, CSBR was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.2M. The 52-week trading range was $5.50 to $8.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.